1. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130: 5–40.
2. Agus DB, Bunn PA Jr, Franklin W et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27 (Suppl. 11): 53–63.
3. Asano M, Yukita A, Matsumoto T et al. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 1998; 17: 185–90.
4. Avner BP, Liao SK, Avner B et al. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Modif 1989; 8: 25–36.
5. Axelrod O, Silverman GJ, Dev V et al. Idiotypic cross-reactivity of immunoglobulins expressed in Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, and mantle %one lymphocytes of secondary B-cell follicles. Blood 1991; 77: 1484–90.